The Khabele lab recently published a new manuscript in BMC Cancer, titled “The Tie2 antagonist rebastinib reduces ovarian cancer growth in a syngeneic murine model.”
Gupta VG, Roby KF, Pathak HB, Godwin AK, Gunewardena S, Khabele D. The Tie2 antagonist rebastinib reduces ovarian cancer growth in a syngeneic murine model. BMC Cancer. 2025 Feb 11;25(1):233. doi: 10.1186/s12885-025-13640- z. PMID: 39930466; PMCID: PMC11812249